So Close, yet so Far: Discrepancies between Uveal and Other Melanomas. A Position Paper from UM Cure 2020.
conjunctival melanoma
cutaneous melanoma
health policy
mucosal melanoma
uveal melanoma
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
22 Jul 2019
22 Jul 2019
Historique:
received:
17
06
2019
revised:
12
07
2019
accepted:
16
07
2019
entrez:
25
7
2019
pubmed:
25
7
2019
medline:
25
7
2019
Statut:
epublish
Résumé
Despite much progress in our understanding of uveal melanoma (UM) over the past decades, this rare tumour is still often misclassified. Although UM, like other melanomas, is very probably derived from melanocytes, it is drastically different from cutaneous melanoma and most other melanoma subtypes in terms of epidemiology, aetiology, biology and clinical features, including an intriguing metastatic hepatotropism. UM carries distinctive prognostic chromosome alterations, somatic mutations and gene expression profiles, allowing an active tailored surveillance strategy and dedicated adjuvant clinical trials. There is no standard systemic treatment for disseminated UM at present. In contrast to cutaneous melanoma, UMs are not
Identifiants
pubmed: 31336679
pii: cancers11071032
doi: 10.3390/cancers11071032
pmc: PMC6678543
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Horizon 2020
ID : UM Cure 2020
Déclaration de conflit d'intérêts
M.R. and S.P. received research grants from Bristol-Myers Squibb (BMS) and Merck Sharp & Dohme. E.K. has consulting/advisory relationships with BMS, Novartis, Roche, Amgen, Pierre-Fabre (honoraria paid to institution). She received research grants from BMS.
Références
Arch Ophthalmol. 2001 May;119(5):670-6
pubmed: 11346394
Am J Clin Oncol. 2002 Jun;25(3):248-55
pubmed: 12040282
Invest Ophthalmol Vis Sci. 2003 Nov;44(11):4651-9
pubmed: 14578381
Ophthalmology. 2004 Apr;111(4):816-21
pubmed: 15051218
Eur J Surg Oncol. 2009 Nov;35(11):1192-7
pubmed: 19329272
Clin Cancer Res. 2010 Dec 15;16(24):6083-92
pubmed: 20975103
J Innate Immun. 2012;4(5-6):454-62
pubmed: 22302072
Lancet Oncol. 2012 Aug;13(8):782-9
pubmed: 22805292
Nat Rev Clin Oncol. 2012 Nov;9(11):631-42
pubmed: 22965154
Nat Rev Cancer. 2013 Mar;13(3):153-9
pubmed: 23550303
Cancer Discov. 2013 Oct;3(10):1122-1129
pubmed: 23861464
Ann Oncol. 2013 Nov;24(11):2911-5
pubmed: 24067719
Br J Ophthalmol. 2014 Jun;98(6):769-74
pubmed: 24169649
J Surg Oncol. 2014 May;109(6):542-7
pubmed: 24357463
Ann Oncol. 2014 Mar;25(3):742-6
pubmed: 24510314
Cancer Cell. 2014 Jun 16;25(6):831-45
pubmed: 24882515
Cancer Cell. 2014 Jun 16;25(6):822-30
pubmed: 24882516
Melanoma Res. 2016 Jun;26(3):300-3
pubmed: 26848796
Lancet Oncol. 2016 Feb;17(2):e52-e61
pubmed: 26868354
Am J Ophthalmol. 2016 Aug;168:217-226
pubmed: 27296487
Oncoimmunology. 2016 Feb 18;5(5):e1143997
pubmed: 27467964
Cancer. 2016 Nov 15;122(21):3344-3353
pubmed: 27533448
Clin Ophthalmol. 2016 Oct 25;10:2113-2119
pubmed: 27822007
Cancer Immunol Immunother. 2017 Jul;66(7):903-912
pubmed: 28391358
Nature. 2017 May 11;545(7653):175-180
pubmed: 28467829
Cochrane Database Syst Rev. 2017 Jun 12;6:CD011129
pubmed: 28603881
Cancer Cell. 2017 Aug 14;32(2):204-220.e15
pubmed: 28810145
Cell Chem Biol. 2017 Sep 21;24(9):1075-1091
pubmed: 28938087
J Clin Oncol. 2018 Apr 20;36(12):1232-1239
pubmed: 29528792
Nat Commun. 2018 May 14;9(1):1866
pubmed: 29760383
Cancer Cell. 2018 Aug 13;34(2):225-241.e8
pubmed: 30107174
EMBO Mol Med. 2019 Feb;11(2):
pubmed: 30610113
Pigment Cell Melanoma Res. 2019 Jul;32(4):564-575
pubmed: 30672666
Immunogenetics. 2019 May;71(5-6):433-436
pubmed: 30714079
Cancer Cell. 2019 Mar 18;35(3):457-472.e5
pubmed: 30773340
Sci Signal. 2019 Mar 19;12(573):null
pubmed: 30890659
Int Ophthalmol Clin. 2019 Spring;59(2):53-63
pubmed: 30908279
Clin Cancer Res. 2019 Jun 21;:null
pubmed: 31227496
Lancet. 1996 May 4;347(9010):1222-5
pubmed: 8622452